T-bet+外周血液中的ILC3在高疾病活性结性脊髓炎中增加
Yang Liu1,2, Yi Shen1,3, Hongbai Ding1
1Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, China.
Heliyon
|January 27, 2025
概括
天生的淋巴细胞 (ILCs),特别是表达T-bet的ILC3,在活性结性脊髓炎 (AS) 中升高. 这些细胞与疾病严重程度相关,这表明它们在AS炎症和潜在的治疗向中起着关键作用.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 脊髓缩性脊柱炎 (AS) 是一种慢性自身免疫性疾病,导致脊柱炎症和融合.
- 系统性炎症是AS的标志,影响脊柱和外周关节.
研究的目的:
- 为了研究先天性淋巴细胞 (ILCs) 在患有活跃结性脊髓炎的患者中的作用.
- 确定ILC子集与AS中的疾病活性之间的相关性.
主要方法:
- 从健康对照组和AS患者 (高/低活性) 收集血液样本.
- 量化系统性炎症 (CRP,ESR) 和疾病活动 (ASDAS,BASDAI).
- 使用流细胞计和Luminex分析了ILC子集,T-bet,RORγt表达和血细胞因子.
主要成果:
- 在高疾病活性AS患者 (AS-HA) 中,总ILC和ILC3频率升高.
- ILC3的频率和数量与疾病严重程度得分呈正相关.
- T-bet+ILC3s和血IL-17A/IFN-γ水平增加,并且与AS-HA中的循环ILC3s相关.
结论:
- 在结性脊柱炎的炎症过程中,T-bet+ILC3s起着至关重要的作用.
- ILC3s代表了管理AS疾病活动的潜在治疗标.
相关概念视频
T Cell Types and Functions
942
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
942
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


